Clinical Trials
- Infectious Disease
Immune signatures of vaccine responses in vulnerable populations: Comparison of influenza vaccines
- Ages21 years and older
- GenderBoth
- Melanoma
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
- Phase 1 Cancers
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
- Immune System
Characterization of Immune Response to Intradermal Flu Vaccination
- Ages18 years - 40 years
- GenderBoth
- Phase 1 Cancers
Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours
- Infectious Disease, COVID-19 Vaccine
The TIPI Study
- Ages18 years - 65 years
- GenderBoth
- Phase 1 Cancers
A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab